Comparison of different MRI sequences in lesion detection and early response evaluation of diffuse large B-cell lymphoma - a whole-body MRI and diffusion-weighted imaging study

NMR in Biomedicine

Volumn 26, Issue 9, 2013, Pages 1186-1194

  Wu, Xingchen ^a,b   Nerisho, Seyoum ^b   Dastidar, Prasun ^a,b   Ryymin, Pertti ^a   Järvenpää, Ritva ^a   Pertovaara, Hannu ^a   Eskola, Hannu ^a,b   Kellokumpu Lehtinen, Pirkko Liisa ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Apparent diffusion coefficient (ADC); Contrast ratio; Diffuse large B cell lymphoma (DLBCL); Diffusion weighted imaging (DWI); MRI; Therapeutic monitoring; Volumetric analysis

Indexed keywords

APPARENT DIFFUSION COEFFICIENT; CONTRAST RATIO; DIFFUSE LARGE B-CELL LYMPHOMA; DIFFUSION WEIGHTED IMAGING; THERAPEUTIC MONITORING;

CHEMOTHERAPY; ONCOLOGY; SURFACE DIFFUSION; TUMORS; VOLUMETRIC ANALYSIS;

MAGNETIC RESONANCE IMAGING;

CYCLOPHOSPHAMIDE; DOXORUBICIN; GADOTERATE MEGLUMINE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; ECHO PLANAR IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LARGE CELL LYMPHOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; VERTEBRA BODY; WHOLE BODY MRI;

APPARENT DIFFUSION COEFFICIENT (ADC); CONTRAST RATIO; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); DIFFUSION-WEIGHTED IMAGING (DWI); MRI; THERAPEUTIC MONITORING; VOLUMETRIC ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DEMOGRAPHY; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TUMOR BURDEN;

EID: 84882250460     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2933     Document Type: Article

References (32)

1. Bosetti C, Levi F, Ferlay J, Lucchini F, Negri E, La Vecchia C. Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic? Int. J. Cancer 2008; 123: 1917-1923.
2. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood, 2008; 111: 504-516.
3. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009; 50 (Suppl 1): 122S-150S.
4. Ngeow JY, Quek RH, Ng DC, Hee SW, Tao M, Lim LC, Tan YH, Lim ST. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann. Oncol. 2009; 20: 1543-1547.
5. Delbeke D, Stroobants S, de Kerviler E, Gisselbrecht C, Meignan M, Conti PS. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist 2009; 14 (Suppl 2): 30-40.
6. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 2007; 25: 579-586.
7. Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 2009; 251: 166-174.
8. Plathow C, Walz M, Lichy MP, Aschoff P, Pfannenberg C, Bock H, Eschmann SM, Claussen CD, Schlemmer HP. [Cost considerations for whole-body MRI and PET/CT as part of oncologic staging]. Radiologie 2008; 48: 384-396.
9. Ghanem N, Lohrmann C, Engelhardt M, Pache G, Uhl M, Saueressig U, Kotter E, Langer M. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur. Radiol. 2006; 16: 1005-1014.
10. Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body MRI for the staging and follow-up of patients with metastasis. Eur. J. Radiol. 2009; 70: 393-400.
11. Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J. Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur. J. Radiol. 2009; 72: 381-387.
12. Perrone A, Guerrisi P, Izzo L, D'Angeli I, Sassi S, Mele LL, Marini M, Mazza D, Marini M. Diffusion-weighted MRI in cervical lymph nodes: differentiation between benign and malignant lesions. Eur. J. Radiol. 2011; 77: 281-286.
13. Zhang Y, Chen J, Shen J, Zhong J, Ye R, Liang B. Apparent diffusion coefficient values of necrotic and solid portion of lymph nodes: differential diagnostic value in cervical lymphadenopathy. Clin. Radiol. 2013; 68: 224-31.
14. Kwee TC, Ludwig I, Uiterwaal CS, van Ufford HM, Vermoolen MA, Fijnheer R, Bierings MB, Nievelstein RA. ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. MAGMA 2011; 24: 1-8.
15. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am. J. Roentgenol. 2007; 188: 1622-1635.
16. Lin C, Luciani A, Itti E, El-Gnaoui T, Vignaud A, Beaussart P, Lin SJ, Belhadj K, Brugières P, Evangelista E, Haioun C, Meignan M, Rahmouni A. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur. Radiol. 2010; 20: 2027-2038.
17. Wu X, Kellokumpu-Lehtinen PL, Pertovaara H, Korkola P, Soimakallio S, Eskola H, Dastidar P. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma - a pilot study: comparison with 2-deoxy-2-fluoro-D-glucose-positron emission tomography/computed tomography. NMR Biomed. 2011; 24: 1181-1190.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009; 45: 228-247.
19. Heinonen T, Dastidar P, Kauppinen P, Malmivuo J, Eskola H. Semi-automatic tool for segmentation and volumetric analysis of medical images. Med. Biol. Eng. Comput. 1998; 36: 291-296.
20. Wu X, Dastidar P, Pertovaara H, Korkola P, Järvenpää R, Rossi M, Kööbi T, Eskola H, Kellokumpu-Lehtinen PL. Early treatment response evaluation in patients with diffuse large B-cell lymphoma-a pilot study comparing volumetric MRI and PET/CT. Mol. Imaging Biol. 2011; 13: 785-792.
21. Rahmouni A, Tempany C, Jones R, Mann R, Yang A, Zerhouni E. Lymphoma: monitoring tumor size and signal intensity with MR imaging. Radiology 1993; 188: 445-451.
22. Huang MQ, Pickup S, Nelson DS, Qiao H, Xu HN, Li LZ, Zhou R, Delikatny EJ, Poptani H, Glickson JD. Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI. NMR Biomed. 2008; 21: 1021-1029.
23. Rahmouni A, Luciani A, Itti E. MRI and PET in monitoring response in lymphoma. Cancer Imaging 2005; 5: 106S-112S.
24. Wang J, Takashima S, Takayama F, Kawakami S, Saito A, Matsushita T, Momose M, Ishiyama T. Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology 2001; 220: 621-630.
25. Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI-a potential new biomarker of response to cancer therapy. Nat. Clin. Pract. Oncol. 2008; 5: 220-233.
26. Heijmen L, Verstappen MC, Ter Voert EE, Punt CJ, Oyen WJ, de Geus-Oei LF, Hermans JJ, Heerschap A, van Laarhoven HW. Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use? Crit. Rev. Oncol. Hematol. 2012; 83: 194-207.
27. Thoeny HC, De Keyzer F. Extracranial applications of diffusion-weighted magnetic resonance imaging. Eur. Radiol. 2007; 17: 1385-1393.
28. Chen Y, Zhong J, Wu H, Chen N. The clinical application of whole-body diffusion-weighted imaging in the early assessment of chemotherapeutic effects in lymphoma: the initial experience. Magn. Reson. Imaging 2012; 30: 165-170.
29. Lin C, Itti E, Luciani A, Zegai B, Lin SJ, Kuhnowski F, Pigneur F, Gaillard I, Paone G, Meignan M, Haioun C, Rahmouni A. Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. Invest. Radiol. 2011; 46: 341-349.
30. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn. Reson. Imaging 2006; 24: 843-847.
31. Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, Khan AP, Helvie M, Meyer CR, Chenevert TL, Rehemtulla A, Ross BD. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin. Cancer Res. 2007; 13: 443-450.
32. Reichardt W, Juettner E, Uhl M, Elverfeldt DV, Kontny U. Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma. Invest. Radiol. 2009; 44: 298-303.